InflaRX Archives

News and Trends 5 Apr 2023

InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment

InflaRx N.V., a German company developing anti-inflammatory therapeutics by targeting the complement system, has announced that Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the U.S. Food…

April 5, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 26 Jul 2022

InflaRx announces plans to apply for Emergency Use Authorization for new COVID-19 drug

A biopharmaceutical company developing anti-inflammatory therapeutics announced today (July 26) that it is going to submit a request for Emergency Use Authorization (EUA). InflaRx made the announcement after encouraging interactions…

July 26, 2022 - 2 minutesmins - By Liza Laws

inflarx trial inflammatory disease fail skin

More News! 6 Jun 2019

Shares Drop 90% as Antibody for Inflammatory Skin Disease Fails Phase II

The German company InflaRx has seen its shares on the Nasdaq plummet after announcing that its treatment for an inflammatory skin disease failed to beat the placebo in a phase…

June 6, 2019 - 2 minutesmins - By Jonathan Smith

Niels Riedemann InflaRx Cover Image Compressed

Interview 11 Apr 2018

Forget Humira, a New Generation of Inflammation Treatments is on the Horizon

Millions of people worldwide suffer from inflammatory diseases, and many are still waiting for effective treatments. A German company, InflaRx, might have one. We spoke to its founder and CEO,…

April 11, 2018 - 5 minutesmins - By Alexander Burik

News and Trends 8 Nov 2017

German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development

InflaRx has announced that its shares will cost $15 when they're launched for the company's IPO, which could bring in over $100M for the biotech. InflaRx focuses on developing monoclonal…

November 8, 2017 - 2 minutesmins - By Alex Dale

More News! 13 Oct 2017

German Biotech Gets €47M To Treat Painful Inflammatory Disease

InflaRx has raised $55M (€47M) in a Series D fundraising in order to get its lead anti-inflammatory drug, IFX-1, through late-stage development. A year after its €31M Series C, InflaRx is closing…

October 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

inflarx inflammation fundraising itx 1 biotech antibody

News and Trends 22 Jul 2016

German Biotech raises extra €31M to get first-in-class Antibody through trials

InflaRx, a German-based biopharma, has raised €31M in a series C fundraising. This is to further advance a potentially first-in-class antibody which targets an acute form of self-inflammation. Based in Jena, InflaRx’s…

July 22, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Jun 2016

German Biotech launches Phase II in a hot Target for Inflammation

InflaRx has treated the first patient in a new Phase II trial, which is studying the potential of its anti-complement antibody in avoiding immunological complications after complex cardiac surgery -…

June 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering